Jianping Kong
Overview
Explore the profile of Jianping Kong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
477
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kong J, Tao W, Sun Y, Xu Y, Li H, Li J
Front Endocrinol (Lausanne)
. 2025 Jan;
15():1376813.
PMID: 39850479
Introduction: Studies have shown a strong correlation between the cardiometabolic index (CMI) and health issues such as diabetes, atherosclerosis, and decreased renal function. Nevertheless, the correlation between CMI and diabetic...
2.
Norman A, Seetharam M, Allred J, Kong J, Opyrchal M, Ma W, et al.
BJC Rep
. 2025 Jan;
3(1):1.
PMID: 39809926
Background: Based on preclinical data showing addition of CDK4/6 inhibitors to gemcitabine was synergistic, ribociclib was evaluated in combination with gemcitabine to determine the maximum tolerated dose (MTD) and dose...
3.
Li Y, Li Z, Yan P, Hua C, Kong J, Wu W, et al.
Science
. 2024 Dec;
387(6736):eadr0393.
PMID: 39666823
Prokaryotes have evolved diverse defense strategies against viral infection, including foreign nucleic acid degradation by CRISPR-Cas systems and DNA and RNA synthesis inhibition through nucleotide pool depletion. Here, we report...
4.
5.
Huang P, Yan P, Guo L, Fei W, Li Z, Liu J, et al.
Cell Res
. 2024 Oct;
34(12):873-876.
PMID: 39448873
No abstract available.
6.
Kong J, Chen L
Eur J Med Res
. 2024 Oct;
29(1):501.
PMID: 39420432
Background: It is known severe influenza infections and idiopathic pulmonary fibrosis (IPF) disease might stimulate each other. Till now, no associated mechanism has been reported. Method: We collected the genetic...
7.
Zheng Z, Li M, Yang J, Zhou X, Chen Y, Silli E, et al.
Int J Biol Macromol
. 2024 Aug;
277(Pt 3):134517.
PMID: 39111497
Fucoidan-coated pH sensitive liposomes were designed for targeted delivery of gemcitabine (FU-GEM PSL) to treat pancreatic cancer (PC). FU-GEM PSL had a particle size of 175.3 ± 4.9 nm, zeta...
8.
Seetharam M, Norman A, Allred J, Kong J, Opyrchal M, Ma W, et al.
Res Sq
. 2024 May;
PMID: 38746220
Background: Based on preclinical data showing addition of CDK4/6 inhibitors to gemcitabine is synergistic, ribociclib was evaluated in combination with gemcitabine to determine the maximum tolerated dose (MTD) and dose...
9.
Liu Y, Kong J, Liu G, Li Z, Xiao Y
Adv Sci (Weinh)
. 2024 May;
11(28):e2401797.
PMID: 38728624
Gene knock-in refers to the insertion of exogenous functional genes into a target genome to achieve continuous expression. Currently, most knock-in tools are based on site-directed nucleases, which can induce...
10.
Huang Y, Li Z, Ma Y, Wu Q, Kong J, Zhao L, et al.
Pharmaceuticals (Basel)
. 2024 Mar;
17(3).
PMID: 38543111
COVID-19, caused by SARS-CoV-2, has emerged as the most destructive emerging infectious disease of the 21st century. Vaccination is an effective method to combat viral diseases. However, due to the...